Unknown PHASE2 INTERVENTIONAL NCT00202423

Use of Cannabinoids in Patients With Multiple Sclerosis

fMRI and Neurophysiological Study Protocol on Cannabinoids in Multiple Sclerosis

Sponsor: S. Andrea Hospital

Interventions Sativex

Updated 5 times since 2017 Last updated: Nov 28, 2005 Started: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Sclerosis, this trial is ongoing. The trial is conducted by S. Andrea Hospital and has accumulated 5 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

S. Andrea Hospital
University of Roma La Sapienza

Data source: S. Andrea Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy